Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 7/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | BCR | P11274 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30107573 | 0.80 | MAPT (0.43) | FFAR1APPADORA2AGRM5ADK | |
| SCHEMBL17714326 | 0.80 | ADK (0.44) | FFAR1APPADORA2AGRM5ADK | |
| SCHEMBL24047399 | 0.80 | MAPT (0.43) | FFAR1APPADORA2AGRM5ADK | |
| SCHEMBL13516538 | 0.74 | GRM5 (0.61) | FFAR1APPADORA2AGRM5ADK | |
| SCHEMBL17714323 | 0.72 | FFAR1 (0.39) | FFAR1APPADORA2AGRM5ADK | |
| SCHEMBL14422883 | 0.72 | KDM4E (0.52) | ADORA2APIN1ABL1BCRKDM4E | |
| SCHEMBL28927186 | 0.71 | FFAR1 (0.41) | FFAR1GRM5ADKGRM4PLAU | |
| SCHEMBL30107567 | 0.71 | FFAR1 (0.41) | FFAR1GRM5ADKGRM4PLAU | |
| SCHEMBL3442581 | 0.70 | GRM5 (0.43) | FFAR1GRM5ABL1BCRALDH1A1 | |
| SCHEMBL15206758 | 0.69 | MAPT (0.44) | APPADORA2AGRM5ADKGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212652-B1 | RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK (CA) | 2021-02-17 | — | — | EP | disclosed |
| EP-3212652-B1 | RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK (CA) | 2021-02-17 | — | — | EP | disclosed |
| US-10875863-B2 | RIPK2 inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2020-12-29 | — | — | US | disclosed |
| CN-107454899-B | RIPK2 inhibitors and methods of treating cancer therewith | 大学健康网络 | 2020-05-29 | — | — | CN | disclosed |
| US-20190225617-A1 | RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2019-07-25 | — | — | US | disclosed |
| US-10239881-B2 | RIPK2 inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2019-03-26 | — | — | US | disclosed |
| US-20180282335-A1 | RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2018-10-04 | — | — | US | disclosed |
| EP-3212652-A1 | RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | University Health Network (CA) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016065461-A1 | RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016065461-A1 | RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2016-05-06 | — | — | WO | disclosed |
| WO-2013078254-A1 | BICYCLIC HETEROARYL DERIVATIVES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282335-A1 | RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | RIPK2, RIPK1, RIPK4 | FFAR1 3130/4885APP 4706/4885ADORA2A 3475/4885 |
| US-10875863-B2 | RIPK2 inhibitors and method of treating cancer with same | RIPK2, RIPK1, RIPK4 | FFAR1 3224/4885APP 4715/4885ADORA2A 3767/4885 |
| US-10239881-B2 | RIPK2 inhibitors and method of treating cancer with same | RIPK2, RIPK1, RIPK4 | FFAR1 3130/4885APP 4706/4885ADORA2A 3475/4885 |
| US-20190225617-A1 | RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | RIPK2, RIPK1, RIPK4 | FFAR1 3224/4885APP 4715/4885ADORA2A 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.